On February 12, 2020 Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) reported that the United States Patent and Trademark Office (USPTO) has granted Xspray a new US patent for HyNap-Dasa (Press release, Xspray, FEB 12, 2020, View Source [SID1234649566]). The new patent, US 10,555,937, covers the pharmaceutical composition of the company’s primary product candidate, HyNap-Dasa. This is Xspray’s fourth product patent in the United States, which is the company’s main market. The patent is valid until January 11, 2033.
"This new patent on our most important market is yet another confirmation of our innovative development work. The formal clinical bioequivalence of the company’s primary product candidate HyNap-Dasa, which has been previously communicated, means that the patent further strengthens our position in negotiations with potential partners", says Per Andersson, CEO of Xspray.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xspray strives to obtain patents for both composition and technology and this new patent claims an amorphous solid dispersion (pharmaceutical composition) of dasatinib.

"Our strategic patent work will generate additional patents in the United States on our product candidates in the near future. The new HyNap-Dasa patent makes it significantly more difficult for other companies to launch a dasatinib product based on amorphous solid dispersion in the United States during the lifetime of the patent, i.e. up until January 2033", Per Andersson concludes.